Home › NDC Lookup › RxCUI directory › RxCUI 2604628

2.4 ML risankizumab-rzaa 150 MG/ML Cartridge [Skyrizi] — RxCUI 2604628

RxNorm drug concept · Semantic branded drug
RxCUI 2604628 Semantic branded drug · SBD ● Current RxNorm concept 10 FDA products 16 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2604628
Official name2.4 ML risankizumab-rzaa 150 MG/ML Cartridge [Skyrizi]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known as2.4 ML Skyrizi 150 MG/ML Cartridge; Skyrizi 360 MG in 2.4 ML Cartridge; Skyrizi 360 MG per 2.4 ML Cartridge
FDA products mapped10
Package NDCs mapped16
Reported Medicaid activity (SDUD)82,904 prescriptions · 50 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Risankizumab-rzaa Injection: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Skyrizi is approved for four conditions: moderate-to-severe plaque psoriasis, active psoriatic arthritis, moderately to severely active Crohn's disease, and moderately to severely...
  • That depends on what you're treating. For psoriasis or psoriatic arthritis, you get a subcutaneous (under-the-skin) injection at weeks 0 and 4, and then roughly every 12 weeks afte...
  • How often do I need to take Skyrizi, and do I have to go to a clinic every time?
  • The most common ones are upper respiratory infections (like colds or sinus infections), headache, fatigue, and reactions at the injection site like redness or soreness. Fungal skin...
📖 Read our full Risankizumab-rzaa Injection guide →

🕸️ Concept Web — How 2.4 ML risankizumab-rzaa 150 MG/ML Cartridge [Sk... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept 2.4 ML risankizumab-rzaa 150 MG/ML Cartridge [Skyrizi] RxCUI 2604628

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 2

    The active substance itself — no strength, form, or brand attached yet.

    • Risankizumab 2166040
    • Risankizumab-rzaa 2166132
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Skyrizi 2166138
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Risankizumab Cartridge 2604624
    • Risankizumab-rzaa Cartridge 2647370
    • Risankizumab Injectable Product 2166134
    • Risankizumab-rzaa Injectable Product 2662921
    • Risankizumab Cartridge [Skyrizi] 2604627
    • Risankizumab-rzaa Cartridge [Skyrizi] 2654365
    • Skyrizi Injectable Product 2166141
    • Cartridge 1649572
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 14 of 15 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • 2.4 ML risankizumab-rzaa 150 MG/ML Cartridge SCD · 2604625
  • Risankizumab-rzaa 150 MG/ML SCDC · 2540690
  • Risankizumab Cartridge SCDF · 2604624
  • Risankizumab-rzaa Cartridge SCDFP · 2647370
  • Risankizumab Injectable Product SCDG · 2166134
  • Risankizumab-rzaa Injectable Product SCDGP · 2662921

Brand-Name Concepts

  • Risankizumab-rzaa 150 MG/ML [Skyrizi] SBDC · 2540693
  • Risankizumab Cartridge [Skyrizi] SBDF · 2604627
  • Risankizumab-rzaa Cartridge [Skyrizi] SBDFP · 2654365
  • Skyrizi Injectable Product SBDG · 2166141
  • Skyrizi BN · 2166138

📦 FDA Products & Package NDCs

10 products · 16 package NDCs
16 package NDCs map to RxCUI 2604628 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00074-1050-01 1 SYRINGE in 1 CARTON (0074-1050-01) / 1 mL in 1 SYRINGE Skyrizi AbbVie Inc. 2021-04-26
00074-1050-70 1 SYRINGE in 1 CARTON (0074-1050-70) / 1 mL in 1 SYRINGE Skyrizi AbbVie Inc. 2021-04-26
00074-1065-01 1 KIT in 1 CARTON (0074-1065-01) * 1.2 mL in 1 CARTRIDGE (... Skyrizi AbbVie Inc. 2022-09-23
00074-1065-02 1 KIT in 1 CARTON (0074-1065-02) * 1.2 mL in 1 CARTRIDGE (... Skyrizi AbbVie Inc. 2022-09-23
00074-1070-01 1 KIT in 1 CARTON (0074-1070-01) * 2.4 mL in 1 CARTRIDGE (... Skyrizi AbbVie Inc. 2022-06-16
00074-1070-02 1 KIT in 1 CARTON (0074-1070-02) * 2.4 mL in 1 CARTRIDGE (... Skyrizi AbbVie Inc. 2022-06-16
00074-2100-01 1 SYRINGE in 1 CARTON (0074-2100-01) / 1 mL in 1 SYRINGE Skyrizi AbbVie Inc. 2021-04-26
00074-2100-70 1 SYRINGE in 1 CARTON (0074-2100-70) / 1 mL in 1 SYRINGE Skyrizi AbbVie Inc. 2021-04-26
00074-4059-01 1 SYRINGE, GLASS in 1 CARTON (0074-4059-01) / .37 mL in 1 S... Skyrizi AbbVie Inc. 2026-06-12
00074-4059-71 1 SYRINGE, GLASS in 1 CARTON (0074-4059-71) / .37 mL in 1 S... Skyrizi AbbVie Inc. 2026-06-12
00074-5015-01 1 VIAL, SINGLE-DOSE in 1 CARTON (0074-5015-01) / 10 mL in 1... Skyrizi AbbVie Inc. 2022-06-16
00074-5015-02 1 VIAL, SINGLE-DOSE in 1 CARTON (0074-5015-02) / 10 mL in 1... Skyrizi AbbVie Inc. 2022-06-16
00074-7040-02 2 CARTON in 1 CARTON (0074-7040-02) / 1 KIT in 1 CARTON *... Skyrizi AbbVie Inc. 2024-03-04
00074-7042-04 4 CARTON in 1 CARTON (0074-7042-04) / 1 KIT in 1 CARTON *... Skyrizi AbbVie Inc. 2024-03-04
00074-8300-01 1 SYRINGE in 1 CARTON (0074-8300-01) / 1.2 mL in 1 SYRINGE Skyrizi AbbVie Inc. 2025-09-03
00074-8350-01 2 SYRINGE in 1 CARTON (0074-8350-01) / 1.2 mL in 1 SYRINGE Skyrizi AbbVie Inc. 2025-09-03
Observed labelers: AbbVie Inc. (16) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🧾 Billing Codes (HCPCS)

Medical billing codes (HCPCS "J-codes") that connect to this concept's packages — used mostly when a clinic or hospital bills for a drug it administers. Each code links to its full billing page.
CodeDescriptorMapped packagesSources
J2327 Inj risankizumab-rzaa 1 mg 1 CMS
⚠ A crosswalk is not coverage: an NDC↔HCPCS mapping does not guarantee any payer covers or pays the code. Always verify the current payer policy before billing.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.